Real-world use of antifibrotic therapy is associated with greater estimated survival in pulmonary fibrosis interstitial lung disease (PF-ILD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback